'Bipolar' Androgen Therapy in Castration-Resistant Prostate Cancer


Get Permission

Resistance to castrating therapy and androgen deprivation therapy in prostate cancer is due in part to adaptive upregulation of androgen receptor levels by castration-resistant prostate cancer cells in the setting of prolonged exposure to a low-testosterone environment. In a study reported in Science Translational Medicine, Schweizer and colleagues investigated whether such androgen receptor overexpression might be exploited in castration-resistant prostate cancer by alternating between exposure to supraphysiologic testosterone levels, to promote castration-resistant prostate cancer cell death, and near-castrate testosterone levels, an approach termed ‘bipolar’ androgen therapy.

In a pilot study, 16 asymptomatic patients with a low/moderate metastatic burden received testosterone cypionate (400 mg intramuscularly, day 1 of 28-day cycle) and etoposide (100 mg, days 1–14). Patients with declining prostate-specific antigen levels after 3 cycles continued on intermittent testosterone monotherapy, with castrating therapy being continued to suppress endogenous testosterone. Bipolar androgen therapy was well tolerated and resulted in prostate-specific antigen response in half of the patients and radiographic response in half. All patients eventually had prostate-specific antigen progression, but four remained on treatment for at least 1 year. Each of 10 evaluable patients had prostate-specific antigen reduction in response to androgen-ablative therapies after bipolar androgen therapy, suggesting that this approach may restore sensitivity to androgen-deprivation therapy.

The investigators concluded: “[Bipolar androgen therapy] shows promise as treatment for [castration-resistant prostate cancer] and should be further evaluated in larger trials.” ■

Schweizer MT, et al. Sci Transl Med 7:269ra2, 2015.


Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.